Marksans Pharma Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Sep ' 25	Sep ' 24	Sep ' 23	Sep ' 22	Mar ' 22

Sales

640.18

563.15

386.71

329.41

342.22

Operating profit

142.13

93.54

64.06

45.38

54.69

Interest

0.62

0.56

0.49

2.11

1.96

Gross profit

201.71

132.49

112.12

83.74

72.44

EPS (Rs)

3.26

2.10

1.67

1.47

1.16

Other income

60.20

39.51

48.55

40.47

19.71

Stock adjustment

-5.46

-7.24

-3.65

-3.91

3.40

Raw material

291.94

250.84

185.62

170.25

163.64

Power and fuel

-

-

-

-

-

Employee expenses

56.36

47.11

35.16

26.87

30.50

Excise

-

-

-

-

-

Admin and selling expenses

-

-

-

-

-

Research and development expenses

-

-

-

-

-

Expenses capitalised

-

-

-

-

-

Other expenses

155.21

178.90

105.53

90.82

89.99

Provisions made

-

-

-

-

-

Depreciation

16.64

13.85

13.22

9.05

9.13

Taxation

37.21

23.42

23.42

15.25

15.82

Net profit / loss

147.86

95.22

75.48

59.44

47.48

Extra ordinary item

-

-

-

-

-

Prior year adjustments

-

-

-

-

-

Equity capital

45.32

45.32

45.32

40.42

40.93

Equity dividend rate

-

-

-

-

-

Agg.of non-prom. shares (Lacs)

-

-

-

-

-

Agg.of non promotoholding (%)

-

-

-

-

-

OPM (%)

22.20

16.61

16.56

13.78

15.98

GPM (%)

28.80

21.98

25.76

22.64

20.01

NPM (%)

21.11

15.80

17.34

16.07

13.12